These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 19579900)
1. [Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder]. García González J; Pérez Fentes D; Aliste Santos C; Suárez Peñaranda JM; León Mateos L; López López R Actas Urol Esp; 2009 Apr; 33(4):447-9. PubMed ID: 19579900 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Sternberg CN; Arena MG; Calabresi F; De Carli P; Platania A; Zeuli M; Giannarelli D; Cancrini A; Pansadoro V Cancer; 1993 Sep; 72(6):1975-82. PubMed ID: 8364877 [TBL] [Abstract][Full Text] [Related]
3. Can patient selection for bladder preservation be based on response to chemotherapy? Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Soga N; Arima K; Sugimura Y Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of advanced transitional-cell carcinoma of the bladder. Miller RS; Torti FM Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829 [TBL] [Abstract][Full Text] [Related]
6. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?]. Matveev BP; Figurin KM Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer. Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736 [TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant chemotherapy with MVAC in bladder carcinoma: Is the feasibility really established? Of: Benadiba et al.: Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences on cystectomy, Pr Urol 2015; 25: 549-554]. Coquard R Prog Urol; 2015 Dec; 25(16):1171-2. PubMed ID: 26420677 [No Abstract] [Full Text] [Related]
10. Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma. Small EJ J Clin Oncol; 2023 Aug; 41(23):3879-3880. PubMed ID: 37549481 [No Abstract] [Full Text] [Related]
11. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698 [TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant chemotherapy in advanced-stage bladder carcinoma. A randomized prospective study comparing MVAC and MVEEC]. Monica B; Larosa M; Frattini A; Macaluso G; Cocconi G; Passalacqua R; Leonardi F Arch Ital Urol Androl; 1994 Dec; 66(5):235-43. PubMed ID: 7812302 [TBL] [Abstract][Full Text] [Related]
13. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Benson MC Ann Oncol; 1999 Nov; 10(11):1269-70. PubMed ID: 10631452 [No Abstract] [Full Text] [Related]
14. Gemcitabine and cisplatin for advanced, metastatic bladder cancer. Cohen MH; Rothmann M J Clin Oncol; 2001 Feb; 19(4):1229-31. PubMed ID: 11181690 [No Abstract] [Full Text] [Related]
15. Is there a role for induction therapy for locally advanced bladder cancer? Soloway MS Urology; 1987 Jun; 29(6):577-83. PubMed ID: 3576880 [No Abstract] [Full Text] [Related]
17. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. Walther PJ Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828 [No Abstract] [Full Text] [Related]
18. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report. Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990 [TBL] [Abstract][Full Text] [Related]
20. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study. de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]